Rhizen Pharmaceuticals S.A. Announces a Scientific Presentation on the Therapeutic Potential of Their Lead Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphomas at the 18th Congress of European Hematology Association, 13-16 June 2013
6/12/2013 8:45:46 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
La Chaux-de-Fonds, Switzerland, June 12, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a scientific poster presentation on the therapeutic potential of its novel, dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, RP6530, in T-cell Lymphomas, at the 18th Congress of the European Hematology Association (EHA) 2013, to be held from June 13-16, at Stockholm, Sweden.
Help employers find you! Check out all the jobs and post your resume.
comments powered by